Medindia
Advertisement

Mayo Clinic Research Suggests Drug Induces Clinical Remissions in Myelofibrosis

by Kathy Jones on December 8, 2013 at 7:56 PM

 Mayo Clinic Research Suggests Drug Induces Clinical Remissions in Myelofibrosis
A Mayo Clinic study has found that imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis.

The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.
Advertisement

"These are early results but they are promising, says the study's lead author, Ayalew Tefferi, M.D. a hematologist at Mayo Clinic. "Some patients in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease."

Myelofibrosis is a chronic myeloid cancer in which bone marrow cells that produce blood cells develop and function abnormally. The result is the formation of scar tissue in the bone marrow (fibrosis), severe anemia that often requires transfusion, weakness, fatigue and an enlarged spleen and liver. Patients with myelofibrosis harbor one of several genetic mutations in their blood stem cells, including JAK2, MPL, CALR, ASXL1 and spliceosome pathway mutations.
Advertisement

"Typically, myelofibrosis is characterized by marrow scarring and although patients may derive symptomatic relief from other treatments such as ruxolitinib, they usually do not revert back to normal bone marrow," Dr. Tefferi says. "Some patients in our trial have reverted back to normal bone marrow."

Imetelstat works by inhibiting telomerase activity in tumor cells which leads to cell death.

Researchers studied imetelstat in 33 patients at Mayo Clinic and have now followed the first 22 patients for a minimum of six months. Among the 22, five patients achieved complete or partial remissions, including reversal of bone marrow fibrosis in four of the five patients. Two of the five patients with complete or partial remission have also experienced complete molecular remissions. The overall response rate was 41 percent.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
Stroop Effect
Plant-Based Diet may Reduce the Risk of COVID-19
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity 

Recommended Reading
Tumor Markers For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false ......
Carcinoid Tumors
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all ......
Pheochromocytoma
Pheochromocytoma is a rare tumor of the adrenal glands that secretes the catecholamines, adrenaline ...
Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors ....
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use